Johnson & Johnson vs Philip Morris International Inc. — how do they compare? Johnson & Johnson trades at $260.69 (market cap $626.09B), while Philip Morris International Inc. trades at $186.25 (market cap $290.24B). The key difference: Johnson & Johnson is far larger — about 2.2× Philip Morris International Inc.'s market cap, and Philip Morris International Inc. pays the higher dividend (3.16%). Which is the better fit depends on your goals.
| JNJ | PM | |
|---|---|---|
Market Cap | $626.09B | $290.24B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $200.17 |
52-Week Low | $172.78 | $144.33 |
Enterprise Value | $654.37B | $333.36B |
Dividend Yield | 2.06% | 3.16% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Philip Morris International (PM) trades at $186.00, down 1.88% on the day, with a neutral technical signal. The stock shows strong profitability with a 25.56% net income margin and has beaten earnings estimates in two of the last three quarters. Recent news highlights a $500 million impairment charge and a lowered profit forecast due to cost pressures, though the IQOS brand was recognized as a top global brand. Analyst consensus remains bullish with a $211.17 price target.
The outlook is mixed; strong cash flow and brand strength support long-term value, but near-term headwinds from cost inflation and illicit market growth pose risks. The current valuation at a P/E of 25.57 appears fair given earnings resilience, making PM a hold for investors tolerant of sector-specific volatility.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →